– DENMARK, Aarhus – NMD Pharma A/S, a clinical-stage biotech company developing first in class, small molecule CLC-1 inhibitors for neuromuscular disorders, today announced that it has raised €35 million financing led by Jeito Capital alongside current investors INKEF Capital, Novo Holdings, Roche Venture Fund, and Lundbeck Foundation.
Concurrent with the financing, Sabine Dandiguian, Managing Partner Jeito Capital has joined the Board as a Non-Executive Director.
Sabine Dandiguian, Managing Partner at Jeito Capital, commented: “The knowledge and R&D process in the field of neuromuscular disorders is outstanding from the NMD Pharma management team. The potential of the pipeline including their lead candidate, NMD670, to treat symptoms of MG, is supported by compelling data. Jeito is proud to have contributed to this financing for NMD Pharma and I look forward to working with Thomas and his team to help support the company’s growth as it enters an exciting time in its development. Jeito is committed to investing in and working closely with companies such as NMD Pharma that are developing breakthrough treatments for patients living with diseases with high unmet needs.”
Proceeds from the financing will be used to support the company as it progresses its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis.
Thomas Holm Pedersen, CEO said: “The closing of this financing round is a testament to the clear vision and ambition of NMD Pharma to become a leader in the field of neuromuscular diseases. It reflects decades of scientific work in the area and the unique potential of our people for growing our development pipeline. Furthermore, we are intrigued with the broad clinical utility of our CLC-1 inhibitor portfolio and look forward to continuing our efforts to provide treatments for patients suffering from neuromuscular diseases. We are pleased to welcome Jeito Capital with Sabine Dandiguian to our Board. Her network of industry contacts and strategic business advice will be invaluable to us as we grow and expand our business.”
About NMD Pharma
NMD Pharma A/S is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on the regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in-vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received seed financing from Novo Holdings, Lundbeckfonden Emerge, and Capnova in 2016, and in 2018 raised a €38 million Series A financing, led by new investor INKEF Capital, together with new investor Roche Venture Fund and existing investors Novo Holdings and Lundbeckfonden Emerge.
For more information: https://www.nmdpharma.com/
About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit-driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States.
For more information: https://www.jeito.life/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.